Phentermine: Research, Dosing, and Where to Buy in 2026

What is Phentermine?

Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.

Phentermine Dosing Protocols

The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.

Where to Buy Phentermine in 2026

Side Effects and Safety

User Reviews

Research Efficacy Snapshot

Published efficacy percentages cited in PubMed trials and named-expert reports about Phentermine. Each line links to the original source.

• "The cohort was 84% female and 45% white, with a mean (SD) baseline age 43.5 (10.7) years and BMI of 37.8 (7.2) kg/m2 ." · Lewis K et al, 2019 PubMed
• "In multivariable models, longer-term users of phentermine experienced more weight loss; patients using continuously for > 12 months lost 7.4% more than the referent group at 24 months (P < 0.001)." · Lewis K et al, 2019 PubMed
• "The composite CVD or death outcome was rare (0.3%, 41 events), with no significant difference in hazard ratios between groups." · Lewis K et al, 2019 PubMed
• "After 56 weeks of treatment, percent weight loss achieved with PHEN/TPM was 10.6%, 8.4%, and 5.1% with 15/92 mg, 7.5/46 mg, and 3.75/23 mg, respectively (p < 0.0001)." · Smith S et al, 2013 PubMed
• "The 52-week extension study (SEQUEL) showed maintained weight loss over 2 years with 9.3% and 10.5% weight loss from baseline for 7.5/46 mg and 15/92 mg PHEN/TPM (p < 0.0001)." · Smith S et al, 2013 PubMed
• "A significantly higher proportion of patients achieved greater than 5%, 10%, or 15% weight loss with PHEN/TPM compared with placebo." · Smith S et al, 2013 PubMed
• "Adverse reactions occurring in 5% or more of study subjects included paresthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth." · Smith S et al, 2013 PubMed
• "Primary endpoints were the percentage change in bodyweight and the proportion of patients achieving at least 5% weight loss." · Gadde K et al, 2011 PubMed
• "38 (4%) patients assigned to placebo, 19 (4%) to phentermine 7·5 mg plus topiramate 46·0 mg, and 73 (7%) to phentermine 15·0 mg plus topiramate 92·0 mg had depression-related adverse events; and 28 (3%), 24 (5%), and 77 (8%), respectively, had anxiety-related adverse events." · Gadde K et al, 2011 PubMed

Phentermine Research Findings in Numbers

Quantitative results quoted verbatim from the indexed peer-reviewed studies and attributed clinical protocols below.

• After 56 weeks of treatment, percent weight loss achieved with PHEN/TPM was 10.6%, 8.4%, and 5.1% with 15/92 mg, 7.5/46 mg, and 3.75/23 mg, respectively (p &lt PMID 23482732
• The 52-week extension study (SEQUEL) showed maintained weight loss over 2 years with 9.3% and 10.5% weight loss from baseline for 7.5/46 mg and 15/92 mg PHEN/TPM (p &lt PMID 23482732
• At 56 weeks, change in bodyweight was -1·4 kg (least-squares mean -1·2%, 95% CI -1·8 to -0·7), -8·1 kg (-7·8%, -8·5 to -7·1 PMID 21481449
• p<0·0001), and -10·2 kg (-9·8%, -10·4 to -9·3 PMID 21481449
• p<0·0001) with phentermine 7·5 mg plus topiramate 46·0 mg, and 687 (70% PMID 21481449
• p<0·0001) with phentermine 15·0 mg plus topiramate 92·0 mg PMID 21481449

Research and Studies

8 PubMed-indexed papers reference Phentermine. Top 8 shown.

Legal Status

Frequently Asked Questions